Navigation Links
Fecal DNA methylation detects gastric and colorectal cancers
Date:8/21/2009

A preliminary evaluation of methylation of two gene promoters in fecal DNA showed promise as a noninvasive method to detect colorectal and gastric cancers, according to a new study published online August 21 in the Journal of the National Cancer Institute.

Because many patients are reluctant to undergo invasive tests for the detection of gastrointestinal cancers, the development of nonintrusive screening tests is desirable. Especially in cancer patients, some cells are sloughed off from the gastrointestinal tract, so small amounts of DNA from these cells present in stool samples can be examined for the presence of cancer biomarkers.

Takeshi Nagasaka, M.D., of the Department of Gastroenterological Surgery and Surgical Oncology at the Okayama University of Graduate School of Medicine, and colleagues analyzed methylation of the RASSF2 and SFRP2 gene promoters from 788 primary gastric and colorectal tissue specimens to determine whether methylation patterns could act as stage-dependent biomarkers of gastrointestinal tumorigenesis. Next, a highly-sensitive assay was developed for the detection of these methylation patterns among 296 fecal DNA specimens from patients with colorectal or gastric tumors.

Extensive methylation at these gene promoters was much more likely to be found in advanced gastric tumors and colorectal tumors than in normal tissue. Methylation markers were detected in 57% of gastric cancer patients, 75% of colorectal cancer patients, and 44% of subjects with advanced colorectal adenomas, but only 10.6% of patients with none of these cancers.

"Selection of adequate biomarkers is critical to the success of any screening methodology," the authors write. "By identifying disease-specific methylation patterns for human fecal DNA from advanced gastric and colorectal tumors, we could more accurately identify subjects at high risk for developing, or having developed, advanced tumors."

In an accompanying editorial, Steven H. Itzkowitz, M.D., of the Dr. Henry D. Janowitz Division of Gastroenterology at the Mount Sinai School of Medicine in New York, said these findings contribute to the field of noninvasive detection of gastrointestinal neoplasia and confirm that even one or two markers may be useful for fecal DNA testing.

"Because some of these cancersare hard to screen with current imaging techniques, further development of fecal DNA as a pan-detection assay for gastrointestinal tract cancers represents an intriguing and exciting new frontier," the editorialist writes.


'/>"/>

Contact: Steve Graff
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Fecal Blood Tests Effective at Spotting Colon Cancer
2. NIH panel seeks to dispel stigma associated with fecal and urinary incontinence
3. Simple, inexpensive and objective tools for the assessment of mucosal inflammation: fecal markers
4. New B-SURE Pads Are The Ideal Alternative Product To Use For Mild Fecal Incontinence - Small, Discrete, Absorbent - Order Online At www.birchwoodmedical.com
5. Flexi-Seal(R) Fecal Management System Receives 2008 Critical Care Nurse Advertising Effectiveness Award
6. Fecal incontinence and quality of life
7. Mouse model highlights histone methylation as distinguishing feature for leukemia subtypes
8. Work with fungus uncovering keys to DNA methylation
9. Rubicon Genomics Announces a Licensing Agreement With Abbott to Develop and Commercialize DNA Methylation Cancer Tests
10. New technique detects specific chromosomal damage, may indicate lung cancer risk
11. Blood protein detects lung cancer, even at earliest stage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... ... in Carnegie, OK, from Dr. Jamie Cameron, with or without a referral. ... to traditional orthodontic treatment. Depending on each patient’s case, treatment with the FASTBRACES ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... buildings (MOBs) and other outpatient facilities, and who are the most active developers? ... those questions, Revista and Healthcare Real Estate Insights (HREI) found that outpatient medical ...
(Date:3/29/2017)... ... March 29, 2017 , ... An inventor from ... rubber bands used in conjunction with my braces always rubbed against the inside ... way to prevent this problem." The O.B.S. was the result of his brainstorming. ...
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one ... cancers and is touted to be the next revolution in our fight against this ... in the form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... Oncology™ (SOGO™), a specialized continuing medical education conference for clinicians who manage some ... Time Square, New York. , The program will be led by co- ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Wound care devices and products are used ... The industry mainly consists of establishments engaged in manufacturing ... wounds caused by mechanical, chemical, thermal, and radiogenic trauma; ... diabetes, skin related diseases, immunological diseases, and other chronic ... the largest region in the wound care devices market ...
(Date:3/29/2017)... Avelas Biosciences, Inc., a clinical stage oncology-focused company dedicated to improving ... Carmine N. Stengone , president and chief executive officer, will present ... th Annual Healthcare Conference on Wednesday, April 5, 2017, at ... Hotel in New York City . ... ...
(Date:3/29/2017)... , March 29, 2017 Today, CVS Health officials ... Kim Reynolds , Department of Public Health Director Gerd ... Steve Lukan in announcing the availability of the opioid ... locations in Iowa.  CVS Health has established a standing order ... CVS Pharmacy to expand access to the medication in the ...
Breaking Medicine Technology: